Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
9 participants
OBSERVATIONAL
2020-09-24
2022-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1-NSE
Patients found to have grossly normal squamous epithelium during endoscopy
No interventions assigned to this group
Group 2-EEG
Patients found to have grossly apparent erosive esophagitis \>1cm with Los Angeles Classification A-D
No interventions assigned to this group
Group 3-NDBE Short
Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Short Segment)
No interventions assigned to this group
Group 4-NDBE Long
Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Long Segment)
No interventions assigned to this group
Group 5
Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
No interventions assigned to this group
Group 6-Esophagectomy
Patients undergoing resection of esophageal cancer
No interventions assigned to this group
Group -7 Pilot and Feasibility
Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of antiinflammatory (aspirin and NSAIDs) or immunosuppressants over the past 1 week.
* Use of nitrate containing medication in the past 1 week.
* Consumption of nitrate rich foods in preceding 24 hours.
* Known allergy to meat or nitrates
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cadman Leggett
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cadman Leggett, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-004618
Identifier Type: -
Identifier Source: org_study_id